statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS PR Newswire BEIJING, April 8, 2024...

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Stock analysts at StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI - Get Free Report) in a note issued to investors on Friday. The firm set a "hold" rating on the...

CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.com

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS PR...

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth...

CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023

CASI Pharmaceuticals, Inc. (NASDAQ:CASI  Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 127,300 shares, a growth of...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Update

StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI  Free Report) in a research note published on Tuesday morning. The firm issued a hold rating on the biotechnology...

CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Casi Pharmaceuticals' BI-1206 shows positive interim Phase 1 data in iNHL

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China CASI Pharmaceuticals Report Positive Interim...

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy...

CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.

Volume	3,669.00
52-Wk High	$8.48
52-Wk Low	$1.85

CASI CASI Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals